Faricimab
Faricimab
Immunoglobulin G1-kappa/lambda with domain crossover, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)] and anti-[Homo sapiens ANGPT2 (angiopoietin 2, Ang2)], humanized and Homo sapiens monoclonal antibody, bispecific
Stoffgruppe
Antineovaskuläres Mittel (VEGF-Inhibitor)